Trailing Novartis and Eli Lilly, radiopharmaceuticals startup Full-Life Technologies nabs $63M to test new PSMA drug
As the US radiopharmaceutical space heats up with the acquisitions of RayzeBio and Point Biopharma, a younger startup based out of China and Belgium has raised $63.3 million to put its first program in the clinic.
Full-Life Technologies’ latest financing is made up of a $47.3 million Series B co-led by Prosperity7 Ventures and an undisclosed healthcare specialist investor, and a $16 million bank loan.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.